At the invitation of Publisher and Chief Editor James Shen, Dr. Eric Bouteiller, International Advisor, Honorary Chairman of RDPAC and French Trade Advisor, joined the Advisory Board of WiCON|Pharma China, which is comprised of 12 distinguished pharmaceutical industry veterans. Until 2017, Eric had been Ipsen’s Senior Vice President for Asia Operations and Chairman of RDPAC.

The following is a member list of the Advisory Board of WiCON|Pharma China with brief introduction of advisors (in the order of last name).

Dr. Eric Bouteiller – Founder of JumoPartners and Senior Advisor at Cornerstone for Life Sciences Practice Group in China, as well as Honorary Chairman of RDPAC and French Trade Advisor. Formerly General Manager of Ipsen China (2001–2011) and the company’s Senior Vice President for Asia Operations (2012-2017). Formerly Chairman for Tianjin Chapter of EUCCC from 2008 to 2011. Formerly Vice Chairman (2011-2015) and Chairman (2016-2017) of RDPAC.

Main Areas of Expertise: Strategic Vision, Alliance Management, Public Affairs and Talent Management.

Brief Bio: Eric Bouteiller is now Founder of JumoPartners and a Senior Advisor at Cornerstone for Life Sciences Practice Group in China. He is also Honorary Chairman of Research & Development based Pharmaceutical Association in China (RDPAC) and lecturing at top Chinese Universities. He joined Ipsen Group as General Manager of Ipsen China (2001–2011). He was then promoted as Senior Vice President for Asia Operations supervising Asian markets for Consumer HealthCare (2012-2017). He is involved in several prominent business organizations in China. He was one of the founder of Tianjin Chapter of the European Union Chamber of Commerce in China (EUCCC) that be chaired from 2008 to 2011. He co-founded the “French HealthCare Alliance for China” (2013-2014), who brings together all French companies investing in China. He was Vice Chairman (2011-2015) then Chairman (2016-2017) of the RDPAC. (https://www.linkedin.com/in/eric-bouteiller-43136310/)

Dr Rob Bryant - Principal, Brychem Business Consulting

Main Areas of Expertise: Worldwide sourcing (including China) of APIs and fine chemicals

Brief Bio: Dr Bryant is the founder of Brychem Business Consulting and a leading consultant to the pharmaceutical industry for their global API and fine chemical sourcing.  Brychem undertakes business development studies, techno-economic assessments, market surveys for companies operating within the pharmaceutical and other science-based industries and also advises investment companies on acquisitions. Prior to becoming a consultant, Rob held senior positions in leading pharmaceutical and fine chemical companies such as GSK.  He studied Natural Sciences at Cambridge University, England, where he obtained his MA and PhD.

Vivian Chen – Formerly Vice President, Corporate Affairs & Government Relations, Lilly China; and Director of Healthcare Economic Policy, RDPAC.

Main Areas of Expertise: Chinese healthcare economics and policies, as well as certain regulatory affairs.

Vivian joined Eli Lilly China in 2012 after working briefly as Director of Public Policy and Center of Excellence for China at Becton Dickinson and earlier at the R&D-based Pharmaceutical Association Committee for five years as Senior Director of Healthcare Economic Policy.  Prior to that, she had been a policy economist with 15 years of professional experience in public policy, international economic development, industrial growth analysis, social security reform and healthcare financing at the World Bank and US Department of Labor in Washington, DC. since 1994. After returning to China in 2003, she provided consulting and research services to the World Bank, Asian Development Bank, International Labor Organization, USAID, as well as IBM, Accenture and the Conference Board.  Her China focus on the broad issues of healthcare reform has been supplemented by analytical projects focused on the program design, financing and implementation of social insurance programs, and healthcare insurance.  Her current focus at RDPAC encompasses healthcare reform policy, particularly with regard to China’s pharmaceutical policy evolving of new drug approval, hospital procurement, drug distribution, pricing, medical insurance and drug reimbursement system. She leads analytic and advocacy efforts for the Healthcare Policy Expert Committee for R&D industry, and has built strong evidence-based research practice for RDPAC to effectively support industry advocacy programs.

Peter Chua – President, Association of Hong Kong Healthcare Professionals; Member, the Pharmacy & Poisons Board of the Hong Kong Government; President, Huatai Pharmaceutical Ltd., Hong Kong; Director, Beijing United Pharmaceutical Ltd.; Justice of Peace (HK); and former President, Hong Kong Pharmaceutical Society.

Main Areas of Expertise: Strategic and policy issues relating to the pharmaceutical industry in Hong Kong and mainland China, and pharmaceutical sales and marketing in Greater China.

Brief Bio: Mr. Chua is a pioneer and leading expert in Chinese pharmaceutical business. He was trained and qualified in London University as a pharmacist in 1970s, and joined Ciba-Geigy (now Novartis) in the early 1980s and spent over 12 years in mainland China cultivating the company’s business in the country and building a nationwide pharmaceutical marketing and sales network. Many of his trainees in the past now hold important marketing, sales and other corporate positions in the Chinese pharmaceutical industry. Mr. Chua now operates a pharmaceutical company in Hong Kong and is a major shareholder and director of Beijing United Pharmaceutical Ltd., a joint venture with Beijing Pharmaceutical Holdings Ltd. (one of the largest pharma distributors in China). He was the President of the Hong Kong Pharmaceutical Society (1993-95) and is now a member of the Pharmacy & Poisons Board of the Hong Kong Government, as well as the President of Hong Kong’s Association of Health Care Professionals. In addition, he is a Justice of Peace (JP) in Hong Kong, a rare honor from the HK government to people of excellence.

Stanley Lau – Co-Founder, iiTalent; and formerly COO, EddingPharm; President, China Biological Products Inc.; GM - Baxter China; GM - Schering Plough China; GM Asia – Searle/Pharmacia; and GM MSD - Taiwan

Main Areas of Expertise: Leadership and management of multinational pharma companies in China and Asia; strategic and policy issues in the Asian healthcare sector; and pharmaceutical sales and marketing in China and Asia.

Brief Bio: Stanley Lau is a seasoned senior executive in the healthcare field for the last twenty five years. He began his career in retail pharmacy and worked as a pharmacy manager in London. He joined Pfizer in 1981 in sales operation and subsequently in marketing position in Hong Kong. Stanley joined Merck Sharp & Dohme in 1987 to become regional sales director responsible for its sales function in Asia region. He was then transferred to the headquarters in New Jersey supporting Latin American and Middle Eastern regions. In 1991 he was appointed as the first general manager of MSD Taiwan, changing the operation from a distributor model to a full subsidiary operation. In 1994, Stanley became general manager of Schering Plough China and set up its first JV in this promising market. He went back to run Asia region as general manager of Searle / Pharmacia from 1999 to 2002. In the last six years he worked at Baxter as general manager of Baxter China and later as strategic advisor to the President of Baxter Asia Pacific region. After retiring from Baxter, he has take senior executive roles in numerous emerging Chinese pharmaceutical companies including Eddingpharm and China Biological Products, and most recently co-founded iiTalent.

Simon Luo –Director of Operations and Country Manager, IQVIA China; Board Director, Chinese Hospital Association; Senior Advisor, National Institute of Hospital Administration under the Ministry of Health; Advisor, China Association of Pharmaceutical Commerce; and Advisor, China Association of Chain Drug Stores.

Main Areas of Expertise: Pharmaceutical and healthcare information management and market/business intelligence.

Brief Bio: Simon Luo is a leading expert and executive in field of Chinese pharmaceutical and healthcare information. He was instrumental in the founding and development of IMS Health’s business in China (including its various national and regional drug purchase audits) and had managed the company’s China operations for over a decade. Before his departure from IMS in early 2009, he was Director of Operations, IMS Health Greater China (China, Taiwan and South Korea) and Board Director of IMS Market Research Consulting (Shanghai) Co. Ltd. From 2002 to 2003, Simon was General Manager, Board Director and Country Manager of IMS Market Research Consulting (Shanghai) Co. Ltd., and between 1998 and 2002, he was Chief Representative and Country Manager of IMS ChinaMetrik Inc. Before IMS acquired ChinaMetrik in 1998, Simon had been Director of China Business and China Project Manager with ChinaMetrik Inc. since 1991. Simon continues to hold many important professional positions including: Board Director, Chinese Hospital Association; Senior Advisor, National Institute of Hospital Administration under the Ministry of Health; Advisor, China Association of Pharmaceutical Commerce; and Advisor, China Association of Chain Drug Stores. Mr. Luo was educated in both China and the United States. He gained a MS degree in medical chemistry from Baylor University, U.S.A. in 1989.

Robert Pollard – Formerly Global Head of Emerging Markets of P\S\L Group; and Director Synovate Healthcare China

Main Areas of Expertise: Market research – China healthcare and pharmaceuticals, healthcare communications and brand management, training and public relations

Brief Bio: Mr. Pollard is a 30 year veteran of the healthcare industry.  Rob is now Global Head of Emerging Markets of P\S\L Group. Before joining the company in 2010, he was Director Synovate Healthcare China. During his early career Mr. Pollard worked with several pharmaceutical companies including Sanofi, Yamanouchi and Quintiles - in New Zealand and throughout Europe.  Robert has worked in marketing, training and sales management roles. He has launched brands in the GI (De-Nol and Pentasa), dermatology (Zineryt and Locoid), anti-infectives (Flemoxin) and urology (Flomax) fields. His brand identity campaign for Flomax (tamsulosin) was nominated as medical advertisement of the year in the UK.  From 1992 – 1995 he was European lead facilitator of “From Vision to Action,” a Pan European Initiative by Yamanouchi to install best practice in Sales Management across Europe following the acquisition of Brocades by Yamanouchi. He joined Isis Market Research Plc in 1995 as General Manager for China.  He was responsible for some of the earliest healthcare market research in China, including for the first time patient record cards, syndicated healthcare research, quarterly market tracking and telephone research.  In 1998 he was appointed Managing Director of Ogilvy Healthcare China, the healthcare communication arm of Ogilvy & Mather.  In 2000 he returned to Isis as a Regional Director.  In October 2003 Isis was acquired by Synovate and is now known as Synovate Healthcare (SHC).  Mr. Pollard writes regularly on China healthcare matters and is often invited to comment in international media as well as present / chair at international healthcare and market research meetings on developments in the China healthcare market. 

Dr. Xiaomei Li Reckford, Formerly Vice President, China Strategic Growth; and CEO, Quintiles Greater China

Main Areas of Expertise: Clinical Research and CRO management in China

Brief Bio:  Dr. Li Reckford is a leading expert of clinical research and CRO management in China. Since 2004, she has been managing the Greater China businesses for Quintiles, the world’s leading pharmaceutical CRO.  Dr. Li Reckford works regularly with SFDA officials and leading clinicians in China on a large number of global and local clinical investigation projects.  She was the Director of Asian Operations for PharmaResearch Corp. between 2000 and 2003, and a consultant and senior clinical scientist with a number of CROs between 1990 and 2000.  Dr. Li Reckford has a PhD (Pharmaceutics) and PharmD from University of North Carolina, and a BS in Pharmacology from the Medical School of Beijing University. She also received advanced medical training in Peking Union Medical College between 1982 and 1984 under the late Chinese Health Minister Chen Minzhang.

Dr. Yan Yan L Starkey - Head of medical affairs, Great China and India, GE Healthcare, Life Science; and formerly Director, New Product Research China Liaison at GlaxoSmithKline Consumer Healthcare.

Main Areas of Expertise:  Clinical research, medical affairs, regulatory affairs of Rx, OTC and consumer healthcare products globally with emphasis on China, India and other Asian countries. Years of clinical practice as a pediatrician in prestigious Chinese hospitals.

Brief Bio:  Dr. Yan Yan L Starkey has 16 years of experience in medical affairs, clinical research, regulatory affairs and project management for both OTC and Rx drugs, covering all phases of clinical trials in Pain/CNS, Cardiovascular, Urology, RT, GI and Oncology and registration programs in China and globally. Yan Yan also has extensive experience in supporting global R&D programs in BRIC markets especially China and India. She is now Head of medical affairs, Great China and India, GE Healthcare, Life Science; and formerly Director of Medical Affairs for GlaxoSmithKline Consumer Healthcare based in New Jersey. Before joining GSK in 2007, Yan Yan worked with many multinational pharmaceutical companies including Novartis, Schering Plough and Yamanouchi in China and the U.S. with growing responsibilities in medical, regulatory and project management areas.  She has a MD degree from the No.4 Military Medical University in China, an M.S. in child neurology from the Peking Union Medical College and an MBA from the University Illinois at Chicago. Prior to joining the pharmaceutical industry, she practiced as a pediatrician in China for six years at Peking Union Medical College Hospital (A Rockefeller Foundation Hospital) and Beijing General Hospital.

Dr. Dong Xie – Chairman and CEO, Frontier Biotechnology Ltd., Chongqing

Main Areas of Expertise: Pharmaceutical/biotech R&D

Brief Bio:  Dr. Xie is an accomplished scientist and entrepreneur. He founded Frontier Biotechnologies Ltd., which is well-known for launching China’s first indigenously-developed innovative anti-AIDS drug, in 2002. Before founding Frontier, Dr. Xie was Director of Research at Tibotec Inc. between 2000 and 2002, Head of Biophysics Laboratory at NCI-Frederick Cancer Research and Development Center between 1995 and 2000, and Director of Operations at the Biocalorimetry Center of Johns Hopkins University between 1993 and 1995. He has a PhD in biophysics from Johns Hopkins University and a BS in physics from Peking University.

Cheryl Q. Xu – Advisor on China, Pharmaceutical Research and Manufacturers of America (PhRMA) and President, Aquila Health Consulting

Main Areas of Expertise: Strategic, policy, pricing and reimbursement issues, government affairs, and regulatory affairs for multinational pharmaceutical companies in China

Brief Bio:  Ms. Xu is a leading consultant to multinational pharmaceutical companies in China on their strategic, policy, pricing and reimbursement issues in the country. She is the Advisor on China for PhRMA and was formerly the Senior Director, Economic Policy, R&D-based Pharmaceutical Association of China (RDPAC).  At RDPAC, Cheryl was responsible for R&D pharmaceutical industry’s economic policies pertaining to China’s healthcare system. She worked closely with industry leaders, US and Chinese government agencies in healthcare sector. Prior to her position at RDPAC, she was based at Pharmacia’s world headquarter and was responsible for business development in Asia Pacific, Japan and Latin America, a US$2 billion sales region. She got her MBA in Finance from Washington University, and BS in Physics from Beijing University.

Dr. Weiping Yang  – CEO, ApolloBio; and formerly President, Nanjing Tongrentang Pharma; Chairman and CEO, Fresenius Kabi China; and Director, RDPAC

Main Areas of Expertise: Leadership and management of multinational and local pharmaceutical companies in China; strategic and policy issues; and pharmaceutical sales and marketing in China.

Brief Bio:  Dr. Yang is a distinguished senior executive and manager in the pharmaceutical industry.  He is now CEO of ApolloBio, a Chinese investment company specializing in China healthcare. He had previously been President of Nanjing Tongrentang Pharma, a leading traditional Chinese medicine player, for a few years after leaving his career at MNCs in 2012. Prior to taking the leadership at Nanjing Tongrentang, he had worked with Fresenius between 1994 and 2012 holding many important positions including the General Manager of Beijing Fresenius Pharmaceutical Ltd., Executive Vice President of Fresenius Kabi with responsibilities on Europe and Asia Pacific, Chief Representative of Fresenius Group’s Shanghai Office, and Chairman and CEO of Fresenius Kabi China Ltd.  Between 2003 and 2005, Dr. Yang left Fresenius briefly to become the President of Beijing Double Crane Pharmaceutical Ltd., one of the largest state-controlled pharmaceutical public companies in China. Before Dr. Yang joined Fresenius, he was the Chief Representative of Hanco’s China Office and the general manager of a Hanco joint venture in China between 1990 and 1994. He held various positions with China Petrochemical International Corporation between 1984 and 1990. Dr. Yang has a PhD in management from Tsinghua University and a MBA from Sino-Europe Management Center.